Nov 07, 2023 9:15 am EST Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
Oct 19, 2023 4:01 pm EDT Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program
Oct 10, 2023 9:00 am EDT Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society
Sep 29, 2023 7:30 am EDT Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
Aug 07, 2023 4:05 pm EDT Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Aug 02, 2023 4:01 pm EDT Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7
Jul 24, 2023 8:30 am EDT Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors
Jul 13, 2023 8:30 am EDT Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors